This condition results from disruption of blood flow or gas exchange between mother and fetus in the perinatal period, occurring just before, during, or immediately after delivery. It is an acquired disorder; no causative genetic variants have been identified in this packet, and inheritance patterns are not applicable.

Specific diagnostic methods are not certified in this packet. Clinical recognition in the neonatal period typically involves neurological assessment; detailed diagnostic criteria are not available in the current record.

No FDA-approved treatments for perinatal asphyxia are listed in this packet. Care is directed at supportive neonatal management aimed at limiting ongoing injury to affected organ systems. Numerous investigational agents carry orphan drug designation for neonatal hypoxic-ischemic encephalopathy and related presentations; none have received marketing approval as of this record.

Certified natural history or long-term outcome data are not included in this packet. Outcomes are understood to vary substantially depending on the severity and duration of oxygen deprivation; specific prognostic data are not certified here.

Perinatal asphyxia is an active research area with numerous clinical trials registered on ClinicalTrials.gov. Trial records include studies examining biomarkers of asphyxia and monitoring tools for neonatal hypoxic-ischemic encephalopathy. Active clinical trials for this condition are listed on ClinicalTrials.gov.